OBR Green Articles (Leukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis))


February 2019Edition

At 2018 ASH experts talked about the ever-increasing uptake of molecular profiling in therapeutic decision-making for patients with AML beyond just risk stratification. Clearly molecular profiling has arrived as a standard in AML disease management,...


June 2018Edition

The enthusiasm for the new CAR-Ts Kymriah and Yescarta has been dampened by limited patient access and uncertainties about cost and reimbursement. As CMS and other payers grapple with coverage decisions, the long-term economic sustainability of these...